Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape

Benjamin M. Ellingson, Caroline Chung, Whitney B. Pope, Jerrold L. Boxerman, Timothy J Kaufmann

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The wide variety of treatment options that exist for glioblastoma, including surgery, ionizing radiation, anti-neoplastic chemotherapies, anti-angiogenic therapies, and active or passive immunotherapies, all may alter aspects of vascular permeability within the tumor and/or normal parenchyma. These alterations manifest as changes in the degree of contrast enhancement or T2-weighted signal hyperintensity on standard anatomic MRI scans, posing a potential challenge for accurate radiographic response assessment for identifying anti-tumor effects. The current review highlights the challenges that remain in differentiating true disease progression from changes due to radiation therapy, including pseudoprogression and radionecrosis, as well as immune or inflammatory changes that may occur as either an undesired result of cytotoxic therapy or as a desired consequence of immunotherapies.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalJournal of Neuro-Oncology
DOIs
StateAccepted/In press - Apr 5 2017

Fingerprint

Glioblastoma
Inflammation
Active Immunotherapy
Neoplasms
Passive Immunization
Capillary Permeability
Ionizing Radiation
Immunotherapy
Disease Progression
Radiotherapy
Therapeutics
Magnetic Resonance Imaging
Drug Therapy

Keywords

  • Glioblastoma
  • Imaging
  • Pseudoprogression
  • Radiation necrosis

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. / Ellingson, Benjamin M.; Chung, Caroline; Pope, Whitney B.; Boxerman, Jerrold L.; Kaufmann, Timothy J.

In: Journal of Neuro-Oncology, 05.04.2017, p. 1-10.

Research output: Contribution to journalArticle

@article{1c7197012c714445a5971b858b719f36,
title = "Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape",
abstract = "The wide variety of treatment options that exist for glioblastoma, including surgery, ionizing radiation, anti-neoplastic chemotherapies, anti-angiogenic therapies, and active or passive immunotherapies, all may alter aspects of vascular permeability within the tumor and/or normal parenchyma. These alterations manifest as changes in the degree of contrast enhancement or T2-weighted signal hyperintensity on standard anatomic MRI scans, posing a potential challenge for accurate radiographic response assessment for identifying anti-tumor effects. The current review highlights the challenges that remain in differentiating true disease progression from changes due to radiation therapy, including pseudoprogression and radionecrosis, as well as immune or inflammatory changes that may occur as either an undesired result of cytotoxic therapy or as a desired consequence of immunotherapies.",
keywords = "Glioblastoma, Imaging, Pseudoprogression, Radiation necrosis",
author = "Ellingson, {Benjamin M.} and Caroline Chung and Pope, {Whitney B.} and Boxerman, {Jerrold L.} and Kaufmann, {Timothy J}",
year = "2017",
month = "4",
day = "5",
doi = "10.1007/s11060-017-2375-2",
language = "English (US)",
pages = "1--10",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape

AU - Ellingson, Benjamin M.

AU - Chung, Caroline

AU - Pope, Whitney B.

AU - Boxerman, Jerrold L.

AU - Kaufmann, Timothy J

PY - 2017/4/5

Y1 - 2017/4/5

N2 - The wide variety of treatment options that exist for glioblastoma, including surgery, ionizing radiation, anti-neoplastic chemotherapies, anti-angiogenic therapies, and active or passive immunotherapies, all may alter aspects of vascular permeability within the tumor and/or normal parenchyma. These alterations manifest as changes in the degree of contrast enhancement or T2-weighted signal hyperintensity on standard anatomic MRI scans, posing a potential challenge for accurate radiographic response assessment for identifying anti-tumor effects. The current review highlights the challenges that remain in differentiating true disease progression from changes due to radiation therapy, including pseudoprogression and radionecrosis, as well as immune or inflammatory changes that may occur as either an undesired result of cytotoxic therapy or as a desired consequence of immunotherapies.

AB - The wide variety of treatment options that exist for glioblastoma, including surgery, ionizing radiation, anti-neoplastic chemotherapies, anti-angiogenic therapies, and active or passive immunotherapies, all may alter aspects of vascular permeability within the tumor and/or normal parenchyma. These alterations manifest as changes in the degree of contrast enhancement or T2-weighted signal hyperintensity on standard anatomic MRI scans, posing a potential challenge for accurate radiographic response assessment for identifying anti-tumor effects. The current review highlights the challenges that remain in differentiating true disease progression from changes due to radiation therapy, including pseudoprogression and radionecrosis, as well as immune or inflammatory changes that may occur as either an undesired result of cytotoxic therapy or as a desired consequence of immunotherapies.

KW - Glioblastoma

KW - Imaging

KW - Pseudoprogression

KW - Radiation necrosis

UR - http://www.scopus.com/inward/record.url?scp=85017170466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017170466&partnerID=8YFLogxK

U2 - 10.1007/s11060-017-2375-2

DO - 10.1007/s11060-017-2375-2

M3 - Article

C2 - 28382534

AN - SCOPUS:85017170466

SP - 1

EP - 10

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

ER -